Journal
ENDOCRINE PATHOLOGY
Volume 27, Issue 2, Pages 115-122Publisher
HUMANA PRESS INC
DOI: 10.1007/s12022-016-9419-6
Keywords
Pituitary; Adenoma; Classification; Genetics; Receptors; Invasion
Categories
Funding
- Novartis Pharma GmbH (Nuremberg, Germany)
- Novo Nordisk Pharma GmbH (Mainz, Germany)
- Pfizer Pharma GmbH (Karlsruhe, Germany)
- Ipsen Pharma GmbH (Ettlingen, Germany)
Ask authors/readers for more resources
The review assesses immunohistochemical findings of somatostatin receptors and of metalloproteinases in different pituitary adenoma types and the significance of molecular genetic data. Current evidence does not support routine immunohistochemical assessment of somatostatin or dopamine receptor subtype expression on hormone-secreting or nonfunctioning pituitary adenomas. Further prospective studies are needed to define its role for clinical decision making. Until then we suggest to restrict membrane receptor profiling to individual cases or for study purposes. The problems of adenoma expansion and invasion are discussed. Despite partially contradictory publications, proteases clearly play a major role in permission of infiltrative growth of pituitary adenomas. Therefore, detection of at least MMP-2, MMP-9, TIMP-2, and uPA seems to be justified. Molecular characterization is important for familial adenomas, adenomas in MEN, Carney complex, and McCune-Albright syndrome and can gain insight into pathogenesis of sporadic adenomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available